Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

APLLTD's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 1.763000
forwardPE 15.854212
debtToEquity 25.224000
earningsGrowth 0.292000
revenueGrowth 0.044000
grossMargins 0.729820
operatingMargins 0.075410
trailingEps 34.330000
forwardEps 48.501310

APLLTD's current ratio being 1.763 shows it has more than enough assets to cover its short-term debts. The company's liquidity position is strong, with ample cash reserves available to meet its immediate financial obligations without strain.
Alembic Pharmaceuticals Limited's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
APLLTD's Debt-to-Equity ratio is low, indicating the company is not over-leveraged. This suggests a prudent approach to financing, with minimal dependence on debt, reducing the financial risk associated with high leverage, and signaling a stable financial outlook.
Alembic Pharmaceuticals Limited's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for Alembic Pharmaceuticals Limited's financial performance.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

APLLTD's price has consistently been situated near the lower end of expected values. This ongoing trend may reflect investor skepticism about the company's growth potential and overall performance.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


14 separate purchases of Alembic Pharmaceuticals Limited stock were made, while market price was at 868.9892926897321 per share.No buy transactions took place in the period under consideration.Increased sells at APLLTD's current price levels point to a possible decline. If this trend of selling continues, it may signal that the stock's price will face further downward pressure, reflecting investor concerns.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


APLLTD has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as APLLTD is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.